Ranbaxy markets Summit's luliconazole in India
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories has launched the antifungal luliconazole (marketed as Lulifin) in India. The product is licensed from Japan's Summit Pharmaceuticals International Corporation (SPI).